Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040310 | 1.00 | CYP1A2 (0.50) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL7908823 | 0.98 | CYP1A2 (0.52) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL6130811 | 0.91 | — | — | |
| SCHEMBL12289432 | 0.91 | — | — | |
| SCHEMBL8635934 | 0.90 | CYP1A2 (0.46) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL4906446 | 0.88 | EPHX1 (0.47) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL4906247 | 0.88 | EPHX1 (0.47) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL4907769 | 0.88 | EPHX1 (0.47) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL4905120 | 0.88 | EPHX1 (0.47) | CYP1A2EPHX1ALDH1A1MEN1HTT | |
| SCHEMBL2927220 | 0.88 | EPHX1 (0.47) | CYP1A2EPHX1ALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504537-B2 | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1466899-A1 | HYDROXAMIC ACID DERIVATIVE AND MMP INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | MMP13, MMP3, MMP2 | CYP1A2 2236/4885EPHX1 1185/4885ALDH1A1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.